Speakers

Prof. Praveen Arany is trained as a dentist and an oral pathologist. He completed a joint Ph.D.-Residency program at Harvard University as a Harvard Presidential Scholar. He has two certificates in clinical translational research from Harvard Medical School and the National Institutes of Health. He pursued postdoctoral fellowships at the Indian Institute of Science, Bangalore; the National Cancer Institute, Bethesda; and the Harvard School of Engineering and Applied Sciences & Wyss Institute, Cambridge. Following his training, he served as an Assistant Clinical Investigator at the National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, from 2012 to 2015. In 2015, he joined the Oral Biology program at the University at Buffalo School of Dental Medicine, New York and is currently an Associate Professor with tenure. He also has several adjunct positions in various institutes, including the National Institute of Aging, N.I.H.; Surgery and Biomedical Engineering, University at Buffalo; School of Nursing, Shepherds University; Tm PAI chair, Sports Medicine and Physical Therapy, Manipal University, India; Visiting Professor, Penang International Dental College, Malaysia, and Visiting Professor, Vishnu Dental College, Bheemavaram, India. 

He has over 150 scientific publications with several well-cited papers to his credit. A complete list of his publications on PubMed is available. His work has over 10500 citations, h-index of 41, i-10 index of 88 (source: Google scholar), and iCITE index of 306 (source: N.I.H.). His work has been featured in many mainstream media highlights in over 70 countries, including Fox News, CNN, MSNBC, Washington Post, BBC, Reuters, and MIT Technology Review, among many others. His research is routinely featured in both print and public media. 

He has received numerous awards, such as the NCI Director’s Young Investigator Award, Wound Healing Society’s Young Investigator Award, Eugene Seidner Scholar, and Horrace Furomoto Young Investigator Award. He has been invited to speak in various national and international forums, reviews for over 100 scientific journals, serves on 9 journal editorial boards, is an Associate Editor in 4, and reviews grants for national and international funding agencies. A comprehensive list of his reviewing and editorial activities is showcasing his broad, multidisciplinary expertise is available here.  

Dr. Arany has held several leadership positions and continued to serve in various positions in the Wound Healing Society (W.H.S.), American Association for Dental Research (A.A.D.R), Academy of Laser Dentistry (A.L.D.), American Society of Lasers in Medicine (A.S.L.M.S), American Dental Education Association (A.D.E.A). He is the immediate past president of the World Association for Photobiomodulation Therapy (W.A.L.T) and North American Association for Photobiomodulation Therapy (N.A.A.L.T), Co-Chair of the International Society of Optics and Photonics (S.P.I.E) conference on Mechanisms of Photobiomodulation therapy and Chair, Technical group on Photobiomodulation, Optica (formerly Optical Society of America), and Co-Director, Center for Excellence in Photobiomodulation in Nursing, West Virginia.  

A few of major contributions to the establishing the field of Photobiomodulation include enabling the standard nomenclature as a NIH/MLM Pubmed MeSH term over 300 other terms such as cold laser treatments or low-level light/laser therapy; demonstrating a novel PBM molecular mechanism involving latent TGF-beta 1 activation that drives tissue resilience, regeneration, and immunomodulation; outlining clinical biomarkers (tissue surface temperature), molecular biomarkers (ATF-4), treatment delivery (target surface irradiance), and dosimetry (Photonic fluence and Einstein) for safe and effective PBM clinical protocols. This has resulted in clinical practice guidelines recommendations for treating several human diseases and promoting wellness, especially in supportive cancer care. 

Dr. Nathan S. Babcock is a distinguished expert in the quantum sciences, with over two decades of experience primarily concentrated in the domain of quantum biology. His academic journey began at two prominent Canadian quantum research institutions: the University of Waterloo in Ontario and the University of Calgary in Alberta. 

After completing his Ph.D. in Physics, Dr. Babcock further advanced his understanding of the intricate relationship between quantum mechanics and biological processes through postdoctoral research in structural biology at Simon Fraser University in British Columbia. His research then led him to explore spin chemistry, conducting groundbreaking studies on radical electron pair models of avian magnetoreception at the Living Systems Institute at the University of Exeter in the UK. 

Dr. Babcock continued to refine his expertise in open quantum systems by investigating the quantum mechanical phenomenon of superradiance in microtubules at the Quantum Biology Laboratory at Howard University in Washington, D.C., where his innovative research on quantum effects in microtubules, garnering significant attention worldwide. His unwavering determination, comprehensive knowledge of the subject, and infectious enthusiasm for the pursuit of physics has given this book its fundamental core. Through his contributions, he aims to ignite curiosity and foster a deeper understanding of the interplay between quantum physics and the living world. 

David Battinelli, MD, is Northwell Health’s physician-in-chief and dean of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. This role follows a transition from his position as Northwell’s senior vice president and chief medical officer (CMO), in which he was responsible for the overall professional management of clinical, education, research and operational issues related to medical and clinical affairs. 

A founding member of the Zucker School of Medicine, he previously served as the vice dean and earlier as the dean for medical education and chaired the committee charged with developing the new medical school’s curriculum. 

Lance Becker, MD, joined Northwell Health in 2015 as chair of the Department of Emergency Medicine at North Shore University Hospital and Long Island Jewish Medical Center, professor and chair of emergency medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, and an investigator at the Feinstein Institute for Medical Research.

A national and international leader in academic emergency medicine, critical care and resuscitation science, Dr. Becker has research interests that are translational and extend across the basic science laboratory into animal models of resuscitation and to human therapies. He has been a leader in the field of resuscitation for more than 25 years, pioneering advances in improving the quality of CPR, AED use, defining the “three-phase” model for cardiac arrest care and therapeutic hypothermia. He has worked closely with the American Heart Association in emphasizing the importance of a “systems of care” approach to improving survival within communities.

Dr. Becker’s cellular studies have helped define reperfusion injury mechanisms, mitochondrial oxidant generation, reactive oxygen and nitrogen species responses to ischemia, apoptotic activation following ischemia, signaling pathways, new cellular cytoprotective strategies and hypothermia protection. He has received numerous honors and awards from organizations such as the American Heart Association, the American College of Emergency Physicians and American Society of Critical Care.

A recipient of prestigious teaching awards, Dr. Becker has mentored many successful researchers. He is a renowned, well-funded researcher who holds many patents for his discoveries. His professional affiliations include membership in the American Heart Association, Society of Academic Emergency Medicine, the US Institute of Medicine, the National Academy of Science, the American College of Emergency Physicians and the American Physiological Society. In addition, he holds many offices in professional and scientific societies, and has organized many national and international scientific meetings. He is an elected member of the Institute of Medicine/National Academy of Medicine.

Before joining Northwell, Dr. Becker was founder and director of the Center for Resuscitation Science at the Hospital of the University of Pennsylvania in Philadelphia, and professor of the Center for Mitochondrial and Epigenomic Medicine at the Children’s Hospital of Philadelphia. He was previously founder and director of the Emergency Resuscitation Center at the University of Chicago and Argonne National Laboratory.

Dr. Becker received his medical degree from the University of Illinois, College of Medicine.

Kevin Beiner is a Chief Operating Officer, Elect at Northwell Health. Beiner has a career focused on healthcare operations and strategic leadership within New York’s largest healthcare provider. Their expertise spans executive leadership, market management, and operational oversight across diverse healthcare settings. 
 
Beiner’s tenure at Northwell Health includes significant roles such as Executive Vice President & President of the Western Market, where they were responsible for the strategic direction and operational performance of a major market segment. Prior to this, they served as Senior Vice President, Deputy Regional Executive Director, and Regional VP of Operations, demonstrating a progressive ascent through operational management. Their earlier contributions as Chief of Staff and Executive Director highlight a deep understanding of organizational dynamics and service delivery. 
 
Further developing their strategic capabilities, Beiner participated in The Health Management Academy as a GE Fellow, focusing on executive peer learning and data-driven insights to accelerate healthcare transformation. Their foundational experience includes roles in operations and financial analysis within the healthcare sector, underscoring a comprehensive grasp of healthcare system management. Beiner holds a Master of Science in Health Care Delivery Science from Dartmouth, an MBA from Hofstra University, and a Bachelor of Arts from the State University of New York at Stony Brook. 

Brian completed his PhD in marine microbiology. He is a Research Fellow at the NICM Health Research Institute, University of Western Sydney and a Research Associate at the Brain and Mind Centre, Sydney University. He research uses molecular biology and has conducted studies of marine microbiology, bioremediation, geomicrobiology, and cellular signalling. His research is currently focussed on the effect of photobiomodulation on the microbiome, including animal models of Parkinson’s disease and chronic kidney disease, as well as clinical trials and case studies. He works closely with Dr Ann Liebert in her studies on the effect of photobiomodulation on the microbiome in Parkinson’s disease, Autism Spectrum Disorder, Diabetic Kidney disease, Oral Mucositis and other neurological and metabolic diseases. He is also interested in the molecular signalling in response to PBM in a various animal models, PBM upregulation of genes and the translational implications of PBMt effects in metabolic and neurodegenerative diseases. Together, he and Ann have published more than 40 journal manuscripts in the past 10 years, with a review of the gutbrain axis receiving the most yearly citations in the International Journal of Molecular Biology. Brian is currently conducting research on peripheral nerve cells at the Brain and Mind Centre. 

Jonathan R. Brestoff, MD, PhD, MPH is an Associate Professor of Pathology and Immunology at WashU Medicine and studies immunometabolism with a focus on understanding how mitochondrial metabolism and mitochondria transfer regulates the function of immune cells. He also serves as the Director of the Initiative for Immunometabolism and Medical Director of the Clinical Flow Cytometry Laboratory. 

Michal Cifra graduated (MSc.) from University of Žilina, Slovakia, in Biomedical Engineering with the thesis “Measurement of spontaneous photon emission from the human body”. He obtained PhD degree in Radioelectronics from Czech Technical University in Prague, Czech Republic, for the thesis “Study of electromagnetic oscillations of yeast cells in kHz-GHz region” which was elaborated in cooperation with the Institute of Electronics and Photonics (IPE), Academy of Sciences of the Czech Republic. His expertise and interests are in electrodynamics, photonics, tubulin, microtubules reactive oxygen species, biological generation of electron and vibrational excited states and measurement of ultra-weak biological electromagnetic fields. Now at the IPE, he is the head of the Bioelectrodynamics research team which studies endogenous electromagnetic fields of living cells. 

Matthew Cimino is a results-driven leader with a strong track record in economic development, business growth, and strategic partnerships. At the Maryland Department of Commerce, he works to attract investment, support innovation-driven industries, and help position Maryland as a national leader in life sciences, technology, and advanced manufacturing. 

Dr. Brian S. Cornblatt is the Director, Personalized & Precision Medicine for Quantum Longevity Clinics and Chief Scientific and Research Officer of Quadrant Clinical Care.  In these roles Dr. Cornblatt focusses in the clinics on uncovering genetic vulnerabilities to detect root causes of dysfunction and helps the treatment teams develop personalized plans for each client to promote true health promotion. As Chief Scientific & Research Officer, Dr. Cornblatt focusses on Quadrant’s medical and scientific investments, guiding translational research initiatives and assisting with product supporting pre-clinical and clinical trial company strategies. He also helps identify and vet potential new investment targets and modify, as needed, the business strategy of companies whose operations will be assisted by the firm. He also guides parent and portfolio companies with product development plans, with an emphasis on creating additional intellectual property, and accelerating both growth and regulatory approvals. 

Dr. Cornblatt is also the cofounder and Chief Scientific Officer of International Nutrition Associates (INA). INA provides clinical trial-backed nutraceuticals to countries throughout Asia and South America as well as novel and high-quality raw materials globally.  Dr. Cornblatt serves as a Board Member for the Johns Hopkins Colorectal Cancer Center of Excellence, Microbiome Alliance for Disease Prevention, and Longevity AI.  

Prior to these roles, Dr. Cornblatt was Chief Medical Officer for BioHarvest Sciences. In this role Dr. Cornblatt oversaw product development and supported company products through the development of translational research initiatives including clinical trials. He also supported Marketing efforts aimed at informing consumers and healthcare workers about the molecular mechanisms of action of company products.  He remains Senior Scientific Consultant for BioHarvest Sciences. As Director, Clinical Research and Science for Nutramax Laboratories Consumer Care, Inc., Dr. Cornblatt developed novel nutraceutical formulations, designed both in vitro and clinical studies (28 total clinical trials over a 13-year period) in support of products, summarized both supporting laboratory and clinical research for healthcare workers and consumers, and developed novel IP and patents (8 patents awarded and 6 provisional patens filed and under review globally).  From 2007-2010 Dr. Cornblatt was the Scientific Director and developer of the Catholic Health Initiatives’ Center for Translational Research (CTR), a combined molecular research laboratory, national biorepository, and diagnostics laboratory. The CTR supported research initiatives throughout CHI’s 42 Oncology centers and worked with the CHI Oncology Network, a clinical trials group that participated in Phase 1 – Phase IV clinical trials, which Dr. Cornblatt oversaw.  In addition, Dr. Cornblatt served on the Catholic Health Institutional Review Board (IRB) as well as the Catholic Health Ventures Fund, where he identified and vetted emerging companies for external investments. 

A Johns Hopkins University School of Medicine Graduate with a Ph.D. in Pharmacology and Molecular Sciences and a postdoctoral fellowship from the Johns Hopkins Bloomberg School of Public Health, Environmental Health Sciences Division of Toxicology, Dr. Cornblatt has been involved in medical research since 1990. In academia, Dr. Cornblatt worked on additional translational research endeavors. Dr. Cornblatt’s main research interests are focused on developing novel formulations comprised of natural based phytochemicals, including isothiocyanates, to minimize chronic inflammation and combat the threats of environmental toxicants. He led development of a novel line of products, Avmacol®, which deliver the essential ingredients needed to support the production of sulforaphane, a phytochemical with many emerging indications. Through his efforts, Avmacol has been used in twenty-eight supporting human clinical studies globally. Dr. Cornblatt served on the board of the Susan Cohan Colon Cancer Foundation. His father is a now a 29-year survivor of metastatic colorectal cancer and his mother a survivor of both colon and uterine cancer.  Both have had profound influences on his career. 

Dr. Cornblatt is the father of two incredible daughters and, when in the United States, spends his nights and weekends outdoors as much as possible, walking or cycling in the rural counties of western Maryland. Throughout much of 2026 and 2027 Dr. Cornblatt will be in New Providence, Bahamas directing the newest Functional Medicine Health Optimization Center and spending as much time outside of the clinic on a beach taking in the amazing views.  

Travis J. A. Craddock, Ph.D. is the Tier 1 Canada Research Chair in Quantum Neurobiology at the University of Waterloo. He is an Associate Professor in the Departments of Biology, and Physics & Astronomy at Waterloo, and a member of the Waterloo Institute for Nanotechnology. Dr. Craddock seeks to understand the basic underlying quantum physical and molecular processes of neuroinflammation to improve diagnosis and identify novel treatment strategies for neuroinflammatory illnesses including Alzheimer’s and Parkinson’s disease. 

Dr. Craddock completed his B.Sc. in physics from the University of Guelph and went on to complete his M.Sc. and Ph.D. in physics at the University of Alberta where his graduate research activities focused on sub-neural biomolecular information processing, and nanoscale neuroscience descriptions of memory, consciousness, and cognitive dysfunction. Prior to joining the University of Waterloo in May 2024 he was as an Associate Professor in the Department of Neuroscience at Nova Southeastern University in Fort Lauderdale FL USA where he served as the Director of Clinical Systems Biology at the Institute for Neuro-Immune Medicine. 

Margaret Crotty is a seasoned public health leader and an Executive in Residence at Columbia University’s Mailman School of Public Health. Most recently, she was President and CEO of JSI, a global non-governmental organization that manages large-scale public health, supply chain, and health technology projects in 42 countries; and improves healthcare quality and access in the US. Margaret also chaired the Board of the Partnership for Supply Chain Management, which manages global procurement and logistics for health commodities, pharmaceuticals, and medical equipment.

Previously, she served as the CEO of Partnership with Children, a provider of community health services; led Save the Children’s flagship multi-billion-dollar campaign to improve global child survival rates; served as CEO of AFS-USA Intercultural Programs; and held roles at EF Education and McKinsey & Company in Jakarta, Shanghai, Hong Kong, and Paris. Margaret is the Chair of the Board of Northwell Health, a member of the Council on Foreign Relations, and a member of health and education boards, including the Serious Fun Children’s Network, the CUNY School of Public Health, Access Global Health, SeaChange Capital Partners and the United Hospital Fund.

Margaret holds an MBA from Harvard Business School, a Masters in Public Health from Columbia University, and a BA in History and African-American Studies from Princeton University.

Michael J. Dowling is one of health care’s most influential voices. He is an award-winning health care leader, author and national keynote speaker who takes a stand on societal issues such as gun violence, corporate social responsibility and immigration—issues many health system leaders shy away from. Mr. Dowling, who was president and CEO of Northwell Health for 23 years, is now CEO emeritus. He will continue to serve Northwell in an advisory capacity, supporting key public health initiatives and focusing on teaching and writing.

Named a “Titan” on the 2025 TIME100 Health list, Mr. Dowling led Northwell to become the only health system on TIME‘s 2025 Most Influential Companies list. He has also been ranked on Modern Healthcare‘s 100 Most Influential People in Healthcare list for 16 consecutive years, achieving the top spot in 2022.

Mr. Dowling is an author; Leading Through a Pandemic: The Inside Story of Humanity, Innovation, and Lessons Learned During the COVID-19 Crisis (2020), After the Roof Caved In: An Immigrant’s Journey from Ireland to America (2020) and The Aging Revolution: The History of Geriatric Health Care and What Really Matters to Older Adults (2024).

Mr. Dowling grew up in Limerick, Ireland.

Cliff Friedman is Founder and Managing Partner of Northwell Health Equity Partners (NHEP). Mr. Friedman formerly served as Chairperson of Huntington Hospital from April 2021 to April 2025 and continues as Chairperson Emeritus. Other roles have included: Northwell Health System Board of Trustees Director and Community Advisory Board Member (2012-2024); Member of the Northwell Investment Committee, a subcommittee of the Finance Committee of the Northwell Board; and Chairperson of the Private Equity Investment Sub-Committee.

As Chairperson of the Private Equity Investment Sub-Committee, Mr. Friedman led the development and execution of the investment strategy used to deliver performance and grow the Northwell private equity portfolio from $25 million into an over $1.3 billion portfolio with GP investments in Buy-Out, PE, growth, venture and secondary funds, co-investments and direct secondaries, and a GP economic stake. Mr. Friedman also served on several fund advisory boards for Northwell’s private equity portfolio.

Mr. Friedman’s unique Northwell board roles during 15 years of transformation and his work on the Northwell private equity portfolio were instrumental in designing NHEP’s strategy to deliver target returns on capital invested, while simultaneously helping to accelerate healthcare transformation.

Prior to his endeavors with Northwell Health, Mr. Friedman filled roles ranging from Chairman to CEO, Founder, Entrepreneur, Board Member, Lead Investor and various senior executive operational positions. He has 40 years of experience in private equity, venture capital, and investment management, with a focus on Media, Communications, Technology, FinTech, and Healthcare. He has served on over 35 private and public corporate Boards, raised capital and supported strategic negotiations both nationally and internationally in countries including the UK, Italy, Spain, Japan, Sweden, Germany, France, Brazil, Mexico and 7 GCC (Gulf Cooperation Counsel) countries. He has a proven record of value creation through a systematic process of working with management teams, board members, and customers, which he leverages to create and negotiate strategic partnerships globally while driving revenue and profitability that positions companies for successful liquidity events for all stakeholders.

Luis Garcia, MD earned his BS in Biology from Boston College (1997), where his genetic research was featured in an international scientific journal. He received his medical degree from Universidad de la Sabana (Bogota, Colombia) in 2005 and served as Medical Director and Chief Science Officer at Salud Futura until June 2010. Licensed to practice medicine and surgery in Colombia, Dr. Garcia developed significant expertise in treating cardiovascular disease, gastrointestinal disorders, diabetes, chronic fatigue, autoimmune conditions, cancer, and age-related health concerns during his tenure at the hospital where he worked. 

Dissatisfied with conventional medicine’s focus on symptom management rather than addressing root causes, Dr. Garcia sought more effective healing modalities by learning from world-renowned CAM experts. At Salud Futura, he integrated neurofeedback, homotoxicology, neural therapy, ozone therapy, chelation, DMSO, and nutritional therapies with traditional Western medicine.  

In 2008, Dr. Garcia attended a seminar on Biomagnetism by founder Dr. Goiz, where he was impressed by the profound health benefits achieved through simple magnets. He began incorporating Biomagnetism into his practice, rigorously testing its effectiveness with conventional diagnostics. After two years, he found that Biomagnetism produced more fundamental health improvements than conventional treatments. As a result, Dr. Garcia closed his practice in Colombia and returned to the U.S. to establish a Biomagnetism practice. 

Dr. Garcia envisions Biomagnetism enhancing the effectiveness and accessibility of quality care worldwide. His work focuses on clinical biomagnetism, practitioner education, and the investigation of magnetic field interactions with biological systems. 

Professor Guy has 40 years’ experience in medical research and global drug development. He founded the drug delivery company Ethical Holdings plc in 1985 and led the company to its NASDAQ listing in 1993; in 1989 he founded Phytopharm plc, of which he was Chairman until 1997; and in 1998 Professor Guy founded GW Pharmaceuticals plc, a world leader in cannabinoid therapeutics, and was Chairman until its sale in May 2021. Geoffrey has been the physician in charge of over 300 clinical studies, author on over 80 scientific publications and has written two books. He holds a BSc in pharmacology from the University of London, an MBBS at St Bartholomew’s Hospital, an MRCS Eng and LRCP London, an LMSSA and a Diploma of Pharmaceutical Medicine from the Royal College of Physicians. Geoffrey was appointed Visiting Professor at the University of Buckingham in 2011 and at the University of Westminster in 2016. He was awarded an Honorary DSc from University of Reading in 2016 and from the University of Westminster in 2024. Geoffrey received the Deloitte Director of the Year Award in Pharmaceuticals and Healthcare in 2011 and several international awards for his contribution to cannabinoids science including the Lifetime Achievement Award from the International Cannabinoid Research Society in 2023. Geoffrey was Chairman of the Board of Trustees of Weldmar Hospicecare Trust for 8 years. In 2018 Professor Guy and his wife Kate established The Guy Foundation Family Trust and in the same year they also formed The Chedington Court Estate Ltd, to run the family estate and invest in Dorset-based farms and businesses. 

Greg Hurst is Associate Director and Principal Mathematician for Human Organ Design at United Therapeutics, where he is developing fully anatomically inspired, 3D-printable human lung equivalents. His work focuses on translating the extreme geometric complexity of pulmonary tissue into manufacturable digital models using computational geometry, algorithm design, high-resolution voxel representations, and fluid-mechanical principles.

He has created one of the most detailed computational lung models to date, featuring approximately 200 million alveoli, 100 billion pulmonary capillary segments, and up to 280 trillion voxels. These models are designed specifically for additive manufacturing workflows, pushing the limits of resolution, scalability, and structural fidelity in biofabrication.

Dr. Maik Hüttemann is a Professor and Division Director of Research at the Center for Molecular Medicine and Genetics at Wayne State University School of Medicine. He received his Ph.D. from the University of Marburg in Germany in 1999. His research focuses on cytochrome c and cytochrome c oxidase; the regulation of mitochondrial oxidative phosphorylation through cell signaling pathways; and the use of noninvasive infrared light waveguide technology for therapy and diagnostics in human diseases, including ischemia-reperfusion injury in the brain and other organs, as well as cancer. 

Ann is a clinician/scientist and Coordinator of Photomolecular Research at the Sydney Adventist Hospital and continues to treat patients at her PBM clinics in Sydney. She is a Research Fellow at the Kolling Institute, Sydney University, and the NICM Health Research Institute, University of Western Sydney and a Visiting Professor in the Faculty of Medicine, Universite de Montpellier, where she teaches on the Diploma of PBM. Ann’s research focusses on molecular mechanisms of photobiomodulation and translational clinical using PBM for Parkinson’s disease, diabetic kidney disease and other neurological and microbiome related diseases. Ann has completed three clinical trials for treatment of Parkinson’s disease, including a randomised placebo-controlled trial. Ann was awarded a Rosalind Franklin Award for 2022 for a study on the treatment of Parkinson’s symptoms with remote PBM. Several manuscripts have resulted from these studies, with more planned. She has spoken at numerous international conferences about the mechanisms of photobiomodulation and her translational research. She is currently Treasurer of the Australian Medical Photobiomodulation Association, is on the scientific advisory board of the World Association of photobiomoduLation Therapy (WALT), is a convenor at SPIE Photonics West 2024 and 2025 and on the Board of the Photobiomodulation Research Foundation, WV, USA. 

Nardo Manaloto is the Managing Partner of Qubits Ventures, a VC firm specializing in early-stage quantum and photonics tech startups. 

Nardo is a computer scientist, deep tech executive, and startup entrepreneur with 25+ years of experience in the full innovation life cycle, emerging technologies, startup ecosystems development, startup acceleration, and scaling, digital transformation, business readiness, and enterprise system transition from legacy systems to modern architectures. 

Nardo also runs a quantum and photonics accelerator in partnership with Founder Institute, a global accelerator in Silicon Valley. 

Carolyn McMakin, MA, DC developed Frequency Specific Microcurrent (FSM) in 1995 and began teaching it in 1997. She has a part-time practice treating chronic pain, does clinical research and teaches FSM seminars in the US and abroad. She has lectured at the National Institutes of Health and at conferences on fibromyalgia and chronic pain in the US, Australia, England, Kuwait, Taiwan and Germany. Her textbook, “Frequency Specific Microcurrent in Pain Management” was published by Elsevier in 2010. Penguin/Random House published “The Resonance Effect; How Frequency Specific Microcurrent is changing medicine” in 2017.

Juliana Mortenson is a physician scientist who has had a life-long interest in the interactions of energy fields with biologic organisms. After completing her medical training, Dr. Mortenson conducted broad ranging experiments – in both biological and inanimate systems – with resonant energies including visible light, microwaves, radio waves, sound waves, magnetic fields, electrical fields, and electrical currents.  Dozens of patents and commercialization (Clene Nanomedicines Inc.) resulted.  Her research into the foundations of physics revealed a rich history of biology and resonant energy dynamics.  Modern quantum biology is building on these foundations and doing the previously impossible. (www.ForgottenPhysics.com)

Mr. Mortenson is the co-inventor of the technology platform developed to produce Clene’s Clean-Surface Nanocrystal (CSN™) therapeutics, as well as the inventor/co-inventor for 30 other U.S. patents and hundreds of corresponding foreign patents. 

Prior to joining Clene, Mr. Mortenson served as former Chief Operating Officer of Research, Development and Manufacturing for an advanced materials-based company of more than 300 employees. In addition to his professional experience, he is a former chief patent counsel responsible for approximately 5,500 patents and patent applications in the U.S. and 44 foreign countries. Mr. Mortenson holds both a Bachelor of Science in physics and a Bachelor of Science in ceramic engineering from Alfred University, a Master of Science in material science from Pennsylvania State University, and a Juris Doctor degree from George Washington University. 

Dr. Nirosha J. Murugan is Canada Research Chair in Tissue Biophysics and a Faculty of Science Distinguished Research Chair at Wilfrid Laurier University, where she leads a multidisciplinary research program investigating the physical basis of life. As an applied biophysicist, her work explores how structured physical signals – such as light, voltage, and magnetism – govern cellular plasticity, tissue regeneration, and the reversal of disease states. Her approach reframes biology not solely as a molecular system, but as a dynamic network governed by first principles in physics. 

Dr. Murugan earned her Ph.D. in Biomolecular Sciences at Laurentian University, where she pioneered quantum-sensor-based technologies for non-invasive cancer detection, now commercialized through HelioFlux Inc. As a postdoctoral fellow in Dr. Michael Levin’s lab at Tufts University, she helped establish ion-channel bioelectricity as a mechanism of tissue patterning and co-developed, in collaboration with Dr. David Kaplan, a silk-hydrogel drug delivery system to induce limb regeneration in non-regenerative species. 

Her lab bridges quantum biology with biomedical engineering to decode how physical signals, acting as carriers of structured information, sculpt the body’s energetic architecture. By mapping how these signals define energy landscapes and reconfigure cellular signaling networks, her work reveals new ways to understand cell state transitions, disease emergence, and therapeutic responsiveness at both the individual and systems level. 

A passionate educator and former Harvard teaching fellow, Dr. Murugan is deeply committed to mentorship and to making biophysics accessible to the next generation of health innovators. Through technology development, interdisciplinary collaboration, and entrepreneurial translation, she aims to bring the biophysics of life into real-world innovations that reprogram diseased states and support a more precise, holistic, and energetically informed model of human health. 

Dr. Wil Ngwa joined ARPA-H in July 2024 from Johns Hopkins Medicine. He was the founding director of the Global Health Catalyst, and co-founder of the Global Oncology University. His award-winning career as a professor in global health and oncology has focused on smart radiotherapy and immunotherapy treatments and innovations for low-cost technologies and approaches to make health care more affordable. Ngwa has served as chair and on the editorial board of multiple scientific journals, and as advisor for the White House Office of Science and Technology Policy.  

He completed his doctoral work in physics at the University of Leipzig in Germany and postdoctoral and clinical training in radiation oncology at M.D. Anderson Cancer Center and Harvard Medical School, blending expertise in medical physics, imaging, nanomedicine, and global health.  

Alistair is a PhD biochemist who began his post-doctoral scientific career studying how cells undergo programmed cell death (apoptosis) at Hammersmith Hospital, London. He continued his research in Edinburgh before moving into industry and worked in clinical safety and medical communications, whilst continuing his academic relationships. Alistair set up his own company in 2005, Broadmind Science, so he could act as an independent scientific advisor. Since that time Alistair has worked with both Geoffrey Guy and Jimmy Bell. From 2010-2015 he was supported by GW Pharmaceuticals in academic positions at Imperial College and the University of Reading. He is now largely a theoretician, specialising in mitochondrial function and the ageing process and what actually defines “health”: his approach is to study the origins of life and evolution, in particular, from the quantum and thermodynamic perspective. He is an author on more than 20 scientific papers and written chapters in two books. In 2019 he became a Visiting Professor at the University of Westminster, and now studies bioenergetics and quantum biology in association with the Research Centre for Optimal Health. 

Martin Picard, PhD, is a Professor of Behavioral Medicine at Columbia University Irving Medical Center and director of the Mitochondrial Psychobiology Group (www.picardlab.org). Pioneering Mitochondrial Psychobiology, Martin has bridged the science of energy and the human experience to advance Healing Science—a field dedicated to understanding the dynamic energetic processes that keep us healthy. As the Chair in Energy and Health at the Columbia Aging Center, he leads NIH-funded research on the mind-mitochondria connection. His group’s work has uncovered connections between subjective experiences and mitochondria in the brain and immune system, linked mental stress to energy metabolism and aging, discovered that hair greying is reversible, and mapped the diversity of mitochondria across the brain and body. Martin collaborates globally to drive scientific and cultural transformation around energy, health, and healing. He is the author of the upcoming book ENERGY. Martin finds inspiration in nature, exploring energy and consciousness with his family, friends, and colleagues.  

Martin received his PhD at McGill University in Canada in 2012, completed postdoctoral training with Doug Wallace at the University of Pennsylvania, and opened his laboratory at Columbia in 2015. 

Camilla Rees is a former financial industry executive in health care corporate finance, venture investing and corporate communications who has more recently been a researcher, author, and award-winning health and environmental activist. She has studied widely in medical, scientific, complementary and alternative, and energy medicine fields, as well as in health enhancement and self-empowerment fields. Today, Camilla serves as a personal and business consultant to change agents, and is a leading activist in the U.S. on the biological and health effects of wireless technologies. 

Camilla is also Senior Policy Advisor, National Institute for Science, Law & Public Policy (NISLAPP), in Washington, D.C., where she has overseen policy papers on electromagnetic fields, the smart grid and telecommunications, including the landmark “Re-Inventing Wires: The Future of Landlines and Networks”. This paper explains why hard-wired, fiber optics to the premises (FTTP) is superior to wireless access networks, and “antenna densification”, and the safer alternative to 5G.  

Camilla has organized dozens of expert panels on technology risks and presented six times at the Commonwealth Club of California, the nation’s oldest and largest public affairs forum. For many years, she was a curriculum developer for a private invitational forum of leading international CEOs focused on productivity, performance and sustainability. She has co-produced TV programs for the PBS stations, two on electromagnetic fields and three on the First Amendment.  

Camilla has helped scientists communicate their findings to the public, media, lawyers, potential joint venture partners and investors. And today, Camilla co-leads 704 No More®, a coalition of 100+ health and environmental advocacy groups supporting a legal and legislative efforts to protect and restore state and local authority over placement of cell towers and antennas. 

Finally, Camilla is an educator in mental imagery working with critically ill patients, and a facilitator of Hellinger Family and Organizational Constellations. Both of these ways of working involve active communication with the invisible dimension to support healing, and often achieve extraordinary results.  

Rory Riggs has been actively involved in the biotechnology industry for over 25 years as a leading entrepreneur, executive, and venture capitalist. He has been the co-founder and chairman/director of many leading companies in healthcare and biotech including: Royalty Pharma, Fibrogen, Sugen, GeneNews and Cibus. He also served as the president and director of Biomatrix Corporation (NYSE: BXM) where he launched Synvisc, an important product in the treatment of osteoarthritis. Rory is currently CEO (Founder) of Locus/Syntax where he is applying attribute-based data analytic technology from healthcare to finance and economics. He was a co-founder and managing member of Scientia Venture’s predecessor: New Venture Funds. 

Rory received a BA from Middlebury College and an MBA from Columbia University. 

Dr. Rothblatt founded United Therapeutics in 1996 and has served as Chairperson and Chief Executive Officer since its inception. Previously, she created the satellite radio company SiriusXM. She is an inventor or co-inventor on nine U.S. patents, with additional applications pending. Her pioneering book, Your Life or Mine: How Geoethics Can Resolve the Conflict Between Private and Public Interests in Xenotransplantation, anticipated the need both for global virus bio-surveillance and a greatly expanded supply of transplantable organs. 

Dr. Rothblatt has also analyzed the socio-ethical issues of human-like cyber competencies, as are emerging from large language models, in her 2014 book Virtually Human. 

Sridevi V. Sarma received her B.S. in Electrical Engineering from Cornell University and her M.S. and Ph.D. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT). She completed postdoctoral training in the Department of Brain and Cognitive Sciences at MIT. She is currently a Professor in the Institute for Computational Medicine and the Department of Biomedical Engineering at Johns Hopkins University. Her research focuses on the modeling, estimation, and control of neural systems, with particular emphasis on therapeutic electrical stimulation for neurological disorders, including epilepsy and chronic pain. She has been invited to speak at over 70 venues worldwide. Together with her undergraduate and graduate trainees, Dr. Sarma has authored over 80 journal articles, one book, two book chapters, and more than 90 peer-reviewed conference proceedings. She is an inventor on 11 patents and disclosures and has contributed to one FDA-cleared medical device. Dr. Sarma is the recipient of numerous honors, including the Burroughs Wellcome Fund Career Award at the Scientific Interface, the Krishna Kumar New Investigator Award from the North American Neuromodulation Society, the Presidential Early Career Award for Scientists and Engineers, the NIH Outstanding Investigator Award for her research in epilepsy, election as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), and the Whiting School of Engineering Robert B. Pond Award for Excellence in Teaching. 

Ramon Soto is the senior vice president and chief marketing and communications officer at Northwell Health. He is responsible for the development and execution of Northwell’s brand strategy, as well as all aspects of marketing and communications, including public relations, digital engagement, strategic marketing, clinical marketing and customer acquisition. He leads Northwell’s mission-driven communication efforts tackling some of the most pressing issues, like gun violence prevention, women’s health, and health equity. Mr. Soto was recently elected to the Ad Council’s Board of Directors. He is also the president of Northwell Studios, which works with production companies, filmmakers and distributors to produce scripted and unscripted content that allows Northwell to tap into the power of storytelling and entertainment.

More than 35 years ago, Dr. Wallace and his colleagues founded the field of human mitochondrial genetics. The mitochondria are the cellular power plants, organelles that generate most of the cell’s energy. The mitochondria also contain their own DNA, the mitochondrial DNA (mtDNA), which encodes the wiring diagram for the cell’s power plants. Dr. Wallace showed that the mtDNA is inherited exclusively from the mother and that genetic alterations in the mtDNA can result is a wide range of metabolic and degenerative diseases as well as being important in cancer and aging.

One of his seminal contributions has been to use mtDNA variation to reconstruct the origin and ancient migrations of women. These studies revealed that humans arose in Africa approximately 200,000 years ago, that women left Africa about 65,000 years ago to colonize Eurasia, and from Siberia, they crossed the Bering land bridge to populate the Americas. Studies on the paternally-inherited Y chromosome showed that men went along too. 

Stephen Wolfram is the creator of Mathematica, Wolfram|Alpha and the Wolfram Language; the author of A New Kind of Science; the founder and CEO of Wolfram Research, and the originator of the Wolfram Physics Project and the Wolfram Institute. 

As senior vice president and chief academic officer, Andrew Yacht directs Northwell Health’s graduate medical education and medical student education programs and supervises administration of continuing medical education, library services, faculty development, advancing health and inclusion initiatives, and global health within the Office of Academic Affairs. He also leads research administration for the Feinstein Institutes for Medical Research, overseeing Feinstein’s scientific affairs, including policy and training, grants management, expense monitoring, regulatory compliance, and scientific development of strategic assets. He serves as ACGME Designated Institutional Official at Northwell as well as Associate Dean for Graduate Medical Education and Professor of Medicine at Zucker School of Medicine at Hofstra/Northwell. 
 
A national presenter and author of articles, textbook chapters and reports, Dr. Yacht is a Fellow of the American College of Physicians and the New York Academy of Medicine. His research interests span graduate and undergraduate medical education and include curriculum design/evaluation, educational program innovation and physician wellbeing. Since the early stages of practicing medicine, Dr. Yacht has focused on the education and mentoring of graduate trainees and medical students. He practices patient-centered care and actively models a humanistic and compassionate approach towards patients. 
 
Dr. Yacht graduated from the University of Massachusetts at Amherst and received his medical degree from SUNY Downstate College of Medicine. He completed his residency and chief residency in internal medicine at Boston University School of Medicine followed by a fellowship in general internal medicine at Boston University Medical Center/ Boston VA Medical Center. He also earned a Master of Science degree in epidemiology from Boston University School of Public Health. 

Stavros Zanos, MD, PhD, obtained his medical degree from Aristotle University in Thessaloniki, Greece. He served as a general medical practitioner and a military physician before training in internal medicine and cardiology and earning a PhD in neuroscience and physiology from the University of Washington School of Medicine, where he also served as senior fellow and instructor. He joined the Feinstein Institutes for Medical Research as an assistant professor in 2017. He is currently associate professor at the Feinstein Institutes and the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, as well as an adjunct professor at the University of Washington School of Medicine and the New York Institute of Technology. At Feinstein, he leads the Translational Neurophysiology Laboratory. 

He is principal investigator in several federal-, foundation- and industry-sponsored projects on basic and translational neuromodulation, cardiovascular science, systems neuroscience and neural engineering. Dr. Zanos is the author of more than 70 peer-reviewed publications. 

Dr. Zanos’ group studies the autonomic nervous system (ANS). Specifically, how the ANS is involved in immune function and physiological homeostasis in health and disease, and how neuromodulation of the ANS can treat conditions with cardiovascular, immune and metabolic dysfunction. His lab uses methods from autonomic neuroscience, neuroanatomy, neural engineering, cardiovascular medicine and neuroimmunology to tackle three main areas of research.